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DNA methylation of oestrogen-regulated
enhancers deﬁnes endocrine sensitivity
in breast cancer
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Julia M.W. Gee10 & Susan J. Clark1,2
Expression of oestrogen receptor (ESR1) determines whether a breast cancer patient receives
endocrine therapy, but does not guarantee patient response. The molecular factors that
deﬁne endocrine response in ESR1-positive breast cancer patients remain poorly understood.
Here we characterize the DNA methylome of endocrine sensitivity and demonstrate the
potential impact of differential DNA methylation on endocrine response in breast cancer.
We show that DNA hypermethylation occurs predominantly at oestrogen-responsive
enhancers and is associated with reduced ESR1 binding and decreased gene expression
of key regulators of ESR1 activity, thus providing a novel mechanism by which endocrine
response is abated in ESR1-positive breast cancers. Conversely, we delineate that ESR1-
responsive enhancer hypomethylation is critical in transition from normal mammary epithelial
cells to endocrine-responsive ESR1-positive cancer. Cumulatively, these novel insights high-
light the potential of ESR1-responsive enhancer methylation to both predict ESR1-positive
disease and stratify ESR1-positive breast cancer patients as responders to endocrine therapy.
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T
he steroid hormone oestrogen activates the oestrogen
receptor (ESR1) to mediate a variety of functions that are
central to the normal development and maintenance of
multiple tissues1. The unique transcriptional response to oestrogen
in each tissue-speciﬁc cell subtype is, in part, regulated by the
epigenome2. Differential DNA methylation and chromatin
remodelling serve to dictate accessibility to functional, oestrogen-
responsive regions of the genome, and thus deﬁne endocrine
response3,4. Inappropriate activation of the ESR1 signalling network
in mammary epithelial cells initiates neoplastic transformation and
drives ESR1-positive breast cancer1. Patients with this disease
commonly receive adjuvant endocrine therapy, which serves to
inhibit ESR1 signalling1,5. Although endocrine therapy reduces the
risk of disease recurrence, a third of patients acquire drug resistance
and experience disease relapse6. Thus, endocrine sensitivity of both
normal breast cells and breast cancer cells is dynamic, raising the
hypothesis that global epigenetic reprogramming of oestrogen-
responsive regions of the genome can modulate endocrine
sensitivity and contributes to the onset of ESR1-positive breast
cancer and the acquisition of endocrine resistance.
While recent studies have provided excellent proof of principle
that the DNA methylation proﬁle of mammary epithelial cells is
altered in early carcinogenesis7, and further modiﬁed in cell
models of endocrine-resistant breast cancer8,9, they do not
address how these changes could directly affect endocrine
sensitivity. Here we identify DNA methylation as a key
determinant of endocrine response in breast cancer. We show
that differential DNA hypermethylation occurs predominantly at
oestrogen-responsive enhancer, not promoter regions, and is
associated with reduced ESR1 binding and decreased gene
expression of key regulators of ESR1 activity. In addition, we
demonstrate that the methylation status of these regulatory
regions is associated with endocrine resistance in human disease,
thus providing a novel mechanism by which endocrine response
is abated in ESR1-positive breast cancers.
Results
Methylation of enhancer loci in endocrine-resistant cells.
To interrogate DNA methylation remodelling as a critical
component of acquired endocrine resistance, we performed
methylation proﬁling in duplicate using the Inﬁnium Human-
Methylation 450 beadchip, on ESR1-positive hormone sensitive
MCF7 cells, and three different well-characterized endocrine-
resistant MCF7-derived cell lines; tamoxifen-resistant (TAMR)10,
fulvestrant-resistant (FASR)11 and oestrogen deprivation-
resistant (MCF7X)12 cells. Density plots showing the correlation
between the DNA methylation proﬁle of parent MCF7 cells
and individual endocrine-resistant cell lines indicate that the
MCF7X and TAMR cells, which are both ESR1 positive10,12,
predominantly gained DNA methylation as indicated by the
increased density of points above the trend line. In contrast,
FASR cells, which are ESR1 negative11, exhibited both hyper and
hypomethylation events relative to parent MCF7 cells as indicated
by a symmetrical density distribution (Fig. 1a–c). We ﬁrst sought
to identify the common differential DNA methylation events
present in each of the three uniquely derived endocrine-resistant
cell models by carrying out paired analyses (that is, each
endocrine-resistant cell line versus MCF7 parent control) and
overlapping the data (Fig. 1d). We found that across the
individual resistant cell lines, 14,749 CpG probes were
commonly hypermethylated (false discovery rate, FDRo0.01),
whereas only 192 probes exhibited shared hypomethylation
(FDRo0.01; Fig. 1d).
To comprehensively characterize the functional genomic location
of differential methylation observed in the endocrine-resistant cell
models, we used ChromHMM segmentation of the MCF7 genome
(previously described in Taberlay et al.13; Fig. 1e). Strikingly,
signiﬁcant enrichment of commonly hypermethylated probes
was exclusively observed in enhancer regions of the genome
(n¼ 3,932 probes, Poo0.0001; hypergeometric test; Fig. 1e). We
next sought to determine whether the enhancer regions identiﬁed as
being more heavily methylated in all endocrine resistance
models were regulated by the ESR1 in the parental MCF7 cells.
Using reprocessed, publically available MCF7 ESR1 (ref. 14),
GATA3 (ref. 15) and FOXA1 ChIP-Seq data16 (two transcription
factors closely associated with ESR1 activity), we found that
enhancer-speciﬁc CpG-hypermethylated probes were enriched in
ESR1-binding sites by approximately sixfold, FOXA1-binding sites
by ﬁvefold and GATA3-binding sites by eightfold (Poo0.0001;
hypergeometric test; Fig. 2a). The greatest number of hyper-
methylated enhancer probes were found to overlap ESR1-binding
sites (n¼ 801), which represents B20% of all hypermethylated
probes in enhancer regions. Signiﬁcantly, 47% (379 out of 801) of
the hypermethylated enhancer probes that were located within an
ESR1-binding site were also located within a FOXA1 and/or
GATA3-binding site (Fig. 2b), which is particularly noteworthy
since these transcription factors cooperatively modulate ESR1-
transcriptional networks by forming a functional enhanceosome17.
Enhancer DNA hypermethylation and diminished ESR1 binding.
Having deﬁned a subset of ESR1-binding sites that overlap
enhancer regions which contain hypermethylated loci in multiple
models of endocrine resistance (see Methods section; n¼ 856 sites,
Supplementary Data 1), we sought to determine whether DNA
methylation affected the intensity of ESR1 binding at these sites.
Using MCF7 and TAMR ESR1 ChIP data14, we compared the
change in ESR1 binding signal intensity at ESR1-enhancer sites that
contained (a) hypermethylated probe(s) to that of all other ESR1-
enhancer sites (Fig. 2c). At methylated ESR1-enhancer sites, there
was a 2.29-log-fold reduction in ESR1 binding in TAMR compared
with MCF7 cells. In contrast, at all other ESR1-enhancer-binding
sites, there was a 0.52-log-fold reduction in ESR1 binding in
TAMR compared with MCF7 cells. Thus, increased methylation at
ESR1-enhancer sites is associated with reduction in ESR1 binding
(Poo0.0001; t-test; Fig. 2c). Four illustrative examples show the
loss of ESR1 binding in the TAMR cells at enhancer regions
that are more heavily methylated in the endocrine-resistant versus
the parent MCF7 (Fig. 2d). The examples include enhancer
regions located within the gene body of death-associated protein
6 (DAXX), golgi to ER trafﬁc protein 4 homologue (GET4; a
member of the BAG6-UBL4A-GET4 DNA damage response/cell
death complex18), ESR1 itself and nuclear receptor co-repressor 2
(NCOR2; Fig. 2d).
Enhancer DNA hypermethylation and related gene expression.
Since the vast majority of ESR1-enhancer-binding sites identiﬁed
as hypermethylated in the endocrine-resistant cell lines compared
with the parent MCF7 cells were intragenic (that is, 617 out of
856, 72% with at least partial overlap; Supplementary Data 1), we
next sought to determine if the DNA methylation of these regions
correlated with the expression of the genes in which they were
located (or closest TSS if intergenic) in human breast cancer.
Using RNA-seq and HM450 methylation data derived from
TCGA breast cohort19 (n¼ 459 patients), we determined that out
of the 856 ESR1-enhancer-binding sites of interest, hyper-
methylation of 328 sites (that is, 38% of ESR1-enhancer sites)
correlated with the reduced expression of the genes with which
they were most closely associated (Spearman’s correlation
coefﬁcient; Po0.001; Supplementary Data 2). The 328 ESR1-
enhancer-binding sites represented 291 unique genes (including
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Figure 1 | Genome-wide DNA methylation proﬁling of endocrine-resistant MCF7 cell models. (a–c) A colorimetric density plot showing correlation
between the HM450 methylation proﬁle of the endocrine-resistant MCF7X (a), TAMR (b) and FASR (c) cells and the parent (endocrine-sensitive) MCF7
cells. The plots show that while the methylation proﬁle of the endocrine-resistant cell lines is strongly correlated with the parent MCF7 cells (MCF7X,
r2¼0.895; TAMR, r2¼0.91; FASR, r2¼0.848; Pearson’s coefﬁcient), both the MCF7X and TAMR cells predominantly gain DNA methylation, whereas the
FASR cells exhibit both hyper- and hypomethylation events relative to parent MCF7 cells. (d) AVenn diagram showing the overlap of HM450 methylation
probes that are more heavily methylated in multiple endocrine-resistant cells compared with the parent MCF7 cells (FDRo0.01). (e) A bar plot showing
the association of differentially methylated HM450 probes that were common to all endocrine-resistant cell lines (compared with the parent MCF7 cells)
across functional/regulatory regions of the genome as determined by MCF7 ChromHMM annotation13. The height of the bars represents the level of
enrichment measured as a ratio between the frequency of hypermethylated (dark blue) or hypomethylated (light blue) probes overlapping a functional
element over the expected frequency if such overlaps were to occur at random in the genome. Statistically signiﬁcant enrichments (P valueoo0.0001;
hypergeometric test) are marked with an asterisk. The numbers of commonly hyper/hypomethylated probes located within each speciﬁc region are
presented in the respective column.
Figure 2 | ESR1 regulation of enhancer sites commonly hypermethylated in endocrine-resistant cell models. (a) A bar plot showing the association of
HM450 probes that were more heavily methylated in endocrine-resistant cell models (compared with MCF7 cells) and also speciﬁcally located in enhancer
regions, across ESR1-, FOXA1- and GATA3-binding sites in MCF7 cells. The height of the bars represents the enrichment measured as a ratio between the
frequency of hypermethylated probes in enhancers overlapping a transcription factor binding site over the expected frequency if such overlaps were to
occur at random across the genome (*P valueoo0.0001; hypergeometric test). The numbers of commonly hyper/hypomethylated probes located within
each speciﬁc region are presented in the columns. (b) AVenn diagram showing the overlap of enhancer-speciﬁc HM450 methylation probes that are more
heavily methylated in multiple endocrine-resistant cell models (compared with MCF7 cells) across ESR1-, FOXA1- and GATA3-binding sites. (c) A box plot
showing the log-fold change (logFC) in ESR1 binding signal at ESR1-enhancer sites that contain at least one commonly hypermethylated probe (yellow box)
and all other ESR1-enhancer sites that overlap a HM450 probe (grey box) in TAMR cells compared with the parent MCF7 cells. The mean logFC in ESR1
binding at hypermethylated ER-enhancer sites is  2.29 and the mean logFC of all other ESR1-enhancer sites is 0.52 (*Poo0.0001; t-test). (The
whiskers of the box plot extend to the most extreme data point, which is no more than 1.5 interquartile range from the box). (d) IGV screen shots to
illustrate the loss of ESR1 binding in TAMR cells compared with the parent MCF7 cells in enhancer regions that overlap methylation probes that are more
heavily methylated in the endocrine-resistant cell models. The MCF7 ChromHMM regions are colour coded as follows—blue, enhancer; yellow, transcribed;
green, promoter; light blue, CTCF; and burgundy, transcribed. The HM450 b values are shown for the MCF7 (green), MCF7X (burgundy), TAMR (orange)
and FASR cells (red) and are representative of biological duplicates. ESR1 ChIP data (blue) is presented in duplicate for both MCF7 and TAMR cells. The
ESR1 enhancers that overlap the regions of endocrine-resistant-speciﬁc hypermethylation are highlighted by the blue boxes.
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those presented in Fig. 2d; Supplementary Data 3). Gene set
enrichment analysis revealed that these genes were over-
represented in gene sets upregulated by ESR1 activation,
downregulated in the acquisition of endocrine resistance and
gene sets lowly expressed in basal versus luminal disease, thus
suggesting that such genes were critical drivers of oestrogen-
driven tumours (Supplementary Fig. 1a). Interestingly, using
unsupervised clustering analysis, this gene set (n¼ 291) stratiﬁes
ESR1-positive and ESR1-negative breast cancer patients
(Supplementary Fig. 1b). Cumulatively, this indicates that the
methylation events occurring throughout the acquisition of
endocrine resistance are serving to facilitate an oestrogen-
independent phenotype reﬂective of a breast cancer subtype
that is refractory to endocrine therapy.
ESR1-enhancer methylation deﬁnes breast cancer subtype. We
next sought to determine whether ESR1-enhancer hypermethy-
lation was indicative of breast cancer subtype. We assessed the
median methylation of all hypermethylated ESR1-enhancer
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Figure 3 | Association between ESR1-enhancer methylation and breast cancer subtype. (a) A box plot showing the median methylation of all HM450
probes that overlap an enhancer region, an ESR1-binding site and demonstrate hypermethylation in endocrine-resistant versus parental MCF7 cells
(n¼801 probes), in normal breast tissue (green; n¼ 97), luminal A (light blue; n¼ 301), luminal B (dark blue; n¼ 52) and ESR1-negative (red; n¼ 105)
breast cancer (data obtained from TCGA breast cancer cohort; *Po0.05, **Poo0.0001; Mann–Whitney U-test). (The whiskers of the box plot extend to
the most extreme data point, which is no more than 1.5 interquartile range from the box). (b) A heatmap showing the methylation proﬁle of 801
ESR1-enhancer-speciﬁc HM450 probes that are more heavily methylated in endocrine-resistant versus parent MCF7 cells in normal breast tissue
(green; n¼97), luminal A (light blue; n¼ 301), luminal B (dark blue; n¼ 52) and ESR1-negative (red; n¼ 105) breast cancer. Columns are patient samples
and rows are HM450 probes. The level of methylation is represented by a colour scale—blue for low levels and red for high levels of methylation.
(c) Box plots showing distribution of methylation b values in normal n¼97 (green), luminal A (light blue; n¼ 301), luminal B (dark blue; n¼ 52) and
ESR1-negative (red; n¼ 105) breast cancer samples across HM450 probes overlapping the ESR1-binding site located within the DAXX enhancer
(Chr6: 33288112-33288670; left panel) and the DAXX promoter region (1,000bp upstream and 100bp downstream of the transcription start site; Chr6:
33290693-33291793; right panel). (The whiskers of the box plots extend to the most extreme data point, which is no more than 1.5 interquartile range
from the box).
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probes (n¼ 801) in TCGA normal (n¼ 97), luminal A (n¼ 301),
luminal B (n¼ 52) and ESR1-negative (n¼ 105) patient HM450
data (Fig. 3a). In normal breast tissue (which is reported to be
B7% ESR1 positive20), the median methylation of the ESR1-
enhancer sites was highest, while median DNA methylation was
signiﬁcantly reduced in luminal A disease (Poo0.0001; Mann–
Whitney U-test), which is indicative of its endocrine-responsive
state. Interestingly, median ESR1-enhancer methylation was
greater in luminal B patients compared with luminal A patients
(P¼ 0.017; Mann–Whitney U-test), who are almost twice as likely
to acquire endocrine resistance21. In ESR1-negative disease,
median methylation was higher than in luminal disease
(versus luminal A, Poo0.0001; versus luminal B, Poo0.0001;
Mann–Whitney U-test; Fig. 3a). A heatmap highlights the
hypomethylated status of the ESR1-enhancer sites in luminal A
disease relative to normal breast tissue and the other breast cancer
subtypes (Fig. 3b). This trend is clearly illustrated at the DAXX
enhancer region in which each CpG within the ESR1-binding site
was hypomethylated in luminal A disease compared with normal
tissue and luminal B and ESR1-negative cancer (Fig. 3c).
Critically, no such variability was apparent at the DAXX
promoter region (1,000 bp upstream and 100 bp downstream of
the transcription start site; Fig. 3c), suggesting a signiﬁcant
regulatory effect of increased methylation at the enhancer locus.
ESR1-enhancer hypermethylation predicts endocrine failure.
Given that ESR1-enhancer hypermethylation is prevalent in
acquired endocrine resistance in vitro (Figs 1e and 2a-d) and in
molecular subclassiﬁcations of breast cancer that are intrinsically
less responsive to endocrine therapy (Fig. 3a–c), we next sought
to determine the methylation status of a panel of these loci in
ESR1-positive (luminal A) breast cancer samples from patients
with different outcomes. Primary samples were sourced from
patients who received endocrine therapy for 5 years and either
experienced relapse-free survival (RFS; 414 years) or those who
had relapsed (o6 years), deﬁned as no relapse-free survival
(n/RFS). Matched local relapse samples were also compared with
the primary n/RFS patient samples. All patients received the same
endocrine therapy (tamoxifen; anonymized patient data is given
in Supplementary Data 4). Using a multiplex bisulphite-PCR
resequencing methodology speciﬁcally devised for formalin-ﬁxed,
parafﬁn-embedded (FFPE)-derived DNA22, the methylation of
multiple CpG sites across a panel of nine oestrogen-responsive
enhancer regions was interrogated (technical duplicate correlates
for all amplicons investigated are shown in Supplementary Fig. 2).
These enhancer regions included those located within DAXX,
MSI2, NCOR2, RXRA and C8orf46 (Fig. 4a–e) and enhancer
regions located within GATA3, ITPK1, ESR1 and GET4
(Supplementary Fig. 3a–d). The assay was repeated with DNA
extracted from biological duplicates of the endocrine-resistant cell
lines and the parent MCF7 cells to ensure its viability
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Figure 4 | ESR1-enhancer DNA hypermethylation in acquired endocrine
resistance in human breast cancer. (a–e) (Left panel) A scatter plot
showing the methylation of individual CpG sites across the ESR1-enhancer
region of interest ((a)-DAXX—Chr6: 33288296-33288372; (b)-MSI2—
Chr17: 55371693-55371786; (c)-NCOR2—Chr12: 124844786-124844883;
(d)-RXRA—Chr9: 137252867-137252967; (e)-C8orf46—Chr8: 67425069-
67425134) in three primary luminal A breast cancers from patients that
received adjuvant endocrine therapy and exhibited RFS (green), three
primary luminal A breast cancers from patients that relapsed following
adjuvant endocrine therapy, deﬁned as no n/RFS (blue) and their matched
local relapse (red). Each dot represents the % methylation at an individual
CpG site for a single patient and the lines represent the average
methylation for the region in primary RFS (green), primary n/RFS (blue)
and matched recurrent tumours (red). (Right panel) Box plots showing the
distribution of methylation values across the ESR1-enhancer region depicted
in the left panel for RFS (green), prognosis/RFS (blue) and matched
recurrent tumours (red); P values correspond to t-test comparison between
RFS versus n/RFS, and n/RFS versus relapse tumours. (The whiskers of the
box plots extend to the most extreme data point, which is no more than
1.5 interquartile range from the box).
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(Supplementary Fig. 4a–i; technical duplicate correlates for all
amplicons investigated are shown in Supplementary Fig. 5). The
average methylation levels detected at all enhancer loci were
signiﬁcantly higher in the recurrent tumours compared with the
matched primary (n/RFS) tumours (DAXX, Po0.0001; ESR1,
Po0.0005; RXRA, Po0.005; GET4, NCOR2, GATA3, MSI2,
Po0.01; C8orf46, ITPK1, Po0.05; t-test), conﬁrming that DNA
methylation at ESR1-responsive enhancers is acquired in resistant
disease (Fig. 4 and Supplementary Fig. 3). The difference in DNA
methylation between RFS and n/RFS primary tumours was less
considerable, although a statistically signiﬁcant difference was
observed for DAXX, Po0.0001; RXRA, Po0.01; C8orf46,
P¼ 0.01; NCOR2 and MSI2 (Po0.05; t-test) enhancer regions
(Fig. 4).
Discussion
Our results support a model whereby ESR1-responsive enhancer
DNA methylation is a fundamental unifying characteristic that
deﬁnes endocrine sensitivity in breast cancer. Interestingly,
previous studies interrogating DNA methylation changes in
endocrine-resistant cell models have predominantly reported
ESR1-regulated promoter methylation8,9,23–26. Our study is the
ﬁrst to combine in depth MCF7 ChromHMM annotation and
genome-wide methylation data from multiple resistance models
to more comprehensively characterize global differential
methylation across diverse genomic regions. We show for the
ﬁrst time that the methylation status of enhancers is associated
with the inhibition of ESR1 binding in vitro and with the
reduced expression of critical regulators and effectors of ESR1
activity in human disease. The identiﬁcation of ESR1-responsive
enhanceosome hypermethylation is both novel and considerably
pertinent in the context of endocrine resistance, since genome-
wide positional analyses deﬁning the set of cis-regulatory
elements that recruit ESR1 in breast cancer cells have revealed
its predominant recruitment to enhancers as opposed to
promoter regions3,27–30. Enhancers are more common than
promoters in the mammalian genome31 and can regulate gene
transcription from tens to thousands of kilobases away by
promoting communication with target promoters through
chromatin looping32,33. In our study, the majority of ESR1-
regulated enhancer regions identiﬁed as hypermethylated in the
resistant cells were located within gene bodies. Strikingly,
hypermethylation of these enhancer regions was frequently
correlated with reduced expression of the host gene, which is in
line with recent studies that have shown that over half of all
enhancer regions are located within a gene body and that the
activation of these enhancers can indeed affect the transcription
of the host gene34,35. Examples of genes whose expression
inversely correlated with ESR1-enhancer DNA methylation
include DAXX and GET4, which have been previously
associated with roles in apoptosis18,36. It is conceivable that the
loss of expression of genes associated with pro-apoptotic
functions facilitates the progression of endocrine resistance by
reducing the efﬁcacy of apoptotic signalling pathways activated by
endocrine therapies37.
Importantly, the ESR1-responsive enhancer hypermethylation
events identiﬁed in the endocrine-resistant cell lines were also
differentially methylated in endocrine-sensitive and endocrine-
resistant breast cancer patient samples. Therefore, it is feasible
that ESR1-responsive enhancer methylation status is reﬂective of
endocrine dependence and could potentially be used to stratify
patients as responders to endocrine therapy. For example,
NCOR2, a gene whose expression has previously been associated
with metastasis-free survival in 620 lymph node-negative patients
with ESR1-positive breast cancer38, was shown to negatively
correlate with ESR1-enhancer methylation. In the present study,
NCOR2 enhancer methylation was signiﬁcantly higher in the
poor (non-relapse-free) prognosis patients, compared with the
good (relapse-free) prognosis primary luminal A breast cancer
patients. Critically, however, in matched recurrent tumours,
enhancer DNA methylation was further increased, supporting the
hypothesis that the endocrine-resistant methylation proﬁle is
acquired, rather than pre-existing, limiting its potential
prognostic value. Intriguingly, it could be a combination of
both acquired and intrinsic methylation differences that give rise
to endocrine-resistant disease. One possible explanation is that
sparse, or ‘seeding’ methylation at ESR1-responsisive enhancer
sites in primary tumours could reﬂect a propensity to gain
extensive methylation that spreads as resistance develops, which
then becomes ﬁrmly established in recurrent disease (as discussed
in ref. 39). Further characterization of ESR1-responsive enhancer
methylation in endocrine-resistant disease will hereafter be an
important area of future investigation, as will be the assessment of
its potential predictive and prognostic application in breast
cancer.
Methods
Cell culture and HumanMethylation450K array. MCF7 breast cancer cells and
the corresponding endocrine-resistant sub-cell lines were kindly given to our
laboratory by Dr Julia Gee (Cardiff University, UK). In brief, MCF7 cells were
maintained in RPMI-1640-based medium containing 5% (v/v) fetal calf serum
(FCS). TAMR MCF7 cells were generated by the long-term culture of MCF7 cells
in phenol red-free RPMI medium containing 5% charcoal stripped FCS and 4-OH-
tamoxifen (1 10 7M; TAM). FASR MCF7 cells were generated by the long-term
culture of MCF7 cells in phenol red-free RPMI medium containing 5% charcoal
stripped FCS and fulvestrant (1 10 7M; FAS). Long-term oestrogen-deprived
MCF7 (MCF7X) cells were generated by the long-term culture of MCF7 cells
in phenol red-free RPMI medium containing 5% charcoal stripped FCS.
Endocrine-resistant sub-lines were established and characterized following 6
months endocrine challenge/oestrogen deprivation exposure10–12. All cell lines
were authenticated by short-tandem repeat proﬁling (Cell Bank, Australia) and
cultured for o6 months after authentication. Genomic DNA was extracted using
the Qiagen DNeasy Blood and Tissue kit according to the manufacturer’s
instructions. HumanMethylation450K arrays were carried out by the Australian
Genome Research Facility (AGRF; Melbourne, Australia).
HM450 analysis. Two biological replicates per condition—MCF7, TAMR,
MCF7X or FASR—were proﬁled on Illumina’s HumanMethylation450K array.
Raw HM450 data was preprocessed and background normalized with the Bicon-
ductor minﬁ package40 using preprocess Illumina(..., bg.correct¼TRUE,
normalize¼ ’controls’, reference¼ 1); resulting M values were used for statistical
analyses and b values for heatmap visualizations and clustering. Differential
methylation analysis of the preprocessed data was performed using the
Bioconductor limma package.
Genomic segmentation and annotation. The ChromHMM segmentation of the
MCF7 genome was obtained from Taberlay et al.13. Enhancer (‘Enhancer’ and
‘EnhancerþCTCF’) and Promoter categories (‘Promoter’, ‘PromoterþCTCF’ and
‘Poised Promoter’) were collapsed into a single ‘Enhancer’ and ‘Promoter’ state
respectively for the purposes of our analysis. RefSeq transcript annotations were
obtained from UCSC genome browser41,42.
ChIP-seq data acquisition and analysis. ESR1 ChiP-seq data for ESR1 in MCF7
and TAMR14 was utilized in this study. Reads were mapped to genome build HG19
(GRCh37) with bowtie and mismatched (43 mismatched bases), multiple
mapping and duplicate reads were excluded from downstream analysis. ESR1
enrichment peaks were identiﬁed with the HOMER software suite43 using the
ﬁndPeaks utility (-style factor -fragLength 200 -size 300 -F 0 -L 0 -C 0 -poisson
1e-06) on each experiment separately. We merged the resulting peaks to produce a
ground set of 120,735 regions for subsequent analysis. Active ESR1 regions were
identiﬁed in MCF7 by comparing the distribution of reads overlapping the ground
set of ESR1 regions in the three MCF7 ESR1 experiments (GSM798423,
GSM798424 and GSM798425) and MCF7 input experiment (GSM798440) with
edegR44. This yielded 54,265 active ESR1 regions in MCF7 (FDRo0.05). A similar
strategy was applied to TAMR data to yield 49,511 ESR1 regions in TAMR cells.
Regions of differential ESR1 binding were identiﬁed by comparing the distribution
of sequence reads in MCF7 and TAMR across the ground set of ESR1 regions using
edgeR and potential variation in copy number was accounted for using DiffBind14.
This analysis resulted in 24,711 regions with statistical signiﬁcant gain (FDR 5%)
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and 32,343 regions with statistical signiﬁcant loss (FDR 5%) of ESR1 binding in
TAMR cells as compared to MCF7 cells. ESR1 peaks overlapping HM450 probes
were assigned to the nearest RefSeq transcript (o20 kb distance) for the purposes
of gene expression analysis. Raw MCF7 GATA3 and FOXA1 ChIP-Seq data was
obtained from Theodorou et al.15 and Hurtado et al.16, respectively. Data were
processed in the same manner as outlined for ESR1 ChIP-seq above.
Gene set enrichment analysis. GSEA was performed against the Molecular
Signatures Database v4.0 (MSigDB)45 C2 Collection. Enrichment was assessed by
hypergeometric testing as implemented in the R stats package.
TCGA data acquisition. DNA methylation analysis utilized clinical data available
through the TCGA Breast Invasive Carcinoma cohort19. Raw HM450 methylation
data (level 1) were obtained from the TCGA data portal (normal samples¼ 97,
ESR1-positive tumours¼ 353 and ESR1-negative tumours¼ 105). ESR1-positive
tumours were further divided into luminal A (lumA¼ 301) and luminal B
(lumB¼ 52) populations using progesterone receptor (PR) expression, such that
lumA were ESR1þ /PRþ and lumB were ESR1þ /PR . Processed RNA-Seq
expression data (level 3) were obtained from TCGA data portal (588 ESR1 positive
tumours with 73 matched normals and 174 ESR1 negative samples with 19
matched normals).
Multiplex bisulﬁte-PCR resequencing of clinical FFPE DNA. Bisulﬁte DNA
conversions were performed using a manual protocol. For each conversion,
B100 ng was bisulﬁte converted at a time. Conversion took place at 80 C for
45min in the presence of 0.3M NaOH, 3.75mM quinone and 2.32M sodium
metabisulﬁte, as per the method of Clark et al.46. The multiplex bisulﬁte-PCR
reaction was performed as follows22. In brief, Promega HotStart GoTaq with Flexi
buffer (M5005) was used with the following components at the indicated
concentrations: 5 green (1 ), CES 5 , (0.5 , N.B. refer to ref. 47 for CES
recipe), MgCl2 (4.5mM), dNTP’s (200 mM each), primers (forward and reverse at
100mM), Hot Start Taq (0.025U ml 1), DNA (2 ng ml 1 ). All primers used are
listed in Supplementary Data 5. Cycling conditions were: 94 C, 5min; 12 cycles of
(95 C, 20 s; 60, 1min); 12 cycles of (94 C, 20 s; 65 C, 1min 30 s); 65 C, 3min, 10
hold. Agencourt XP beads were using to clean-up and concentrate the multiplex
reaction for subsequent barcoding (that is, addition of Illumina p5/p7 sequences
and sample-speciﬁc DNA barcodes). The barcoding PCR used the following
reagents at the indicated ﬁnal concentrations in a 100-ml reaction: 1 GoTaq
Green Flexi buffer; 0.25 CES; 4.5mM MgCl2; 200 mM dNTPs; 0.05U ml 1
HotStart Taq; 25 ml of pooled template after Agencourt XP bead clean-up; and 20 ml
MiSeq (Fluidigm PN FLD-100-3771). Cycling conditions were: 94 C, 5min;
9 cycles of (97 C, 15 s; 60 C, 30 s; 72 C, 2min); 72 C, 2min; 6 C, 5min. MiSeq
sequencing was performed used the MiSeq Reagent Kit v2, 300 cycle; PN MS-102-
2002. Bioinformatic analysis started with adaptor trimming using Trim galore
(options: --length 100). Mapping used the Bismark methylation mapping
programme48 running Bowtie2 (ref. 49) (options: --bowtie2 -N 1 -L 15 --bam -p 2
--score L,-0.6,-0.6 --non_directional; bismark_methylation_extractor -s -
merge_non_CpG –comprehensive --cytosine_report). To reduce computational
overhead, mapping took place against only those genomic regions which were
being investigated, plus an additional 100 bp–1 kb of ﬂanking sequence.
Clinical sample acquisition and DNA extraction. FFPE breast cancer samples
were obtained from the St George Hospital, Kogarah, Australia (Ethics approval
reference from St George Hospital Human Research Ethics Committee is 96/84).
The deidentiﬁed haematoxylin–eosin-stained sections were reviewed by a pathol-
ogist and representative tumour areas were marked and blocks were cored
accordingly. Genomic DNA was extracted using the Qiagen AllPrep DNA/RNA
FFPE kit according to the manufacturer’s instructions.
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